157 related articles for article (PubMed ID: 31137488)
1. Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer.
Simon B; Harrer DC; Schuler-Thurner B; Schuler G; Uslu U
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31137488
[TBL] [Abstract][Full Text] [Related]
2. Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma.
Uslu U; Schuler G; Dörrie J; Schaft N
Exp Dermatol; 2016 Nov; 25(11):872-879. PubMed ID: 27246630
[TBL] [Abstract][Full Text] [Related]
3. Generation of CD8(+) T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy.
Höfflin S; Prommersberger S; Uslu U; Schuler G; Schmidt CW; Lennerz V; Dörrie J; Schaft N
Cancer Biol Ther; 2015; 16(9):1323-31. PubMed ID: 26178065
[TBL] [Abstract][Full Text] [Related]
4. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
5. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
[TBL] [Abstract][Full Text] [Related]
6. Human T cells expressing two additional receptors (TETARs) specific for HIV-1 recognize both epitopes.
Hofmann C; Höfflin S; Hückelhoven A; Bergmann S; Harrer E; Schuler G; Dörrie J; Schaft N; Harrer T
Blood; 2011 Nov; 118(19):5174-7. PubMed ID: 21926350
[TBL] [Abstract][Full Text] [Related]
7. Enhancing lentiviral transduction to generate melanoma-specific human T cells for cancer immunotherapy.
Simon B; Harrer DC; Thirion C; Schuler-Thurner B; Schuler G; Uslu U
J Immunol Methods; 2019 Sep; 472():55-64. PubMed ID: 31207210
[TBL] [Abstract][Full Text] [Related]
8. The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma.
Simon B; Wiesinger M; März J; Wistuba-Hamprecht K; Weide B; Schuler-Thurner B; Schuler G; Dörrie J; Uslu U
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30103488
[TBL] [Abstract][Full Text] [Related]
9. Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone.
Krug C; Birkholz K; Paulus A; Schwenkert M; Schmidt P; Hoffmann N; Hombach A; Fey G; Abken H; Schuler G; Schuler-Thurner B; Dörrie J; Schaft N
Cancer Immunol Immunother; 2015 Dec; 64(12):1623-35. PubMed ID: 26515978
[TBL] [Abstract][Full Text] [Related]
10. A TCR-based Chimeric Antigen Receptor.
Walseng E; Köksal H; Sektioglu IM; Fåne A; Skorstad G; Kvalheim G; Gaudernack G; Inderberg EM; Wälchli S
Sci Rep; 2017 Sep; 7(1):10713. PubMed ID: 28878363
[TBL] [Abstract][Full Text] [Related]
11. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
12. CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia.
Harrer DC; Schuler G; Dörrie J; Schaft N
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31195686
[TBL] [Abstract][Full Text] [Related]
13. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA
J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359
[TBL] [Abstract][Full Text] [Related]
14. Genetic engineering of T cell specificity for immunotherapy of cancer.
Willemsen RA; Debets R; Chames P; Bolhuis RL
Hum Immunol; 2003 Jan; 64(1):56-68. PubMed ID: 12507815
[TBL] [Abstract][Full Text] [Related]
15. Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance.
Wiesinger M; März J; Kummer M; Schuler G; Dörrie J; Schuler-Thurner B; Schaft N
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31426437
[TBL] [Abstract][Full Text] [Related]
16. Driving CAR T cells towards dermatologic oncology.
Uslu U
J Dtsch Dermatol Ges; 2021 Mar; 19(3):359-362. PubMed ID: 33591642
[TBL] [Abstract][Full Text] [Related]
17. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.
Krebs K; Böttinger N; Huang LR; Chmielewski M; Arzberger S; Gasteiger G; Jäger C; Schmitt E; Bohne F; Aichler M; Uckert W; Abken H; Heikenwalder M; Knolle P; Protzer U
Gastroenterology; 2013 Aug; 145(2):456-65. PubMed ID: 23639914
[TBL] [Abstract][Full Text] [Related]
18. Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing.
Campillo-Davo D; Fujiki F; Van den Bergh JMJ; De Reu H; Smits ELJM; Goossens H; Sugiyama H; Lion E; Berneman ZN; Van Tendeloo V
Front Immunol; 2018; 9():2503. PubMed ID: 30464762
[TBL] [Abstract][Full Text] [Related]
19. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.
Wang Y; Geldres C; Ferrone S; Dotti G
Expert Opin Ther Targets; 2015; 19(10):1339-50. PubMed ID: 26190756
[TBL] [Abstract][Full Text] [Related]
20. Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.
Slaney CY; von Scheidt B; Davenport AJ; Beavis PA; Westwood JA; Mardiana S; Tscharke DC; Ellis S; Prince HM; Trapani JA; Johnstone RW; Smyth MJ; Teng MW; Ali A; Yu Z; Rosenberg SA; Restifo NP; Neeson P; Darcy PK; Kershaw MH
Clin Cancer Res; 2017 May; 23(10):2478-2490. PubMed ID: 27965307
[No Abstract] [Full Text] [Related]
[Next] [New Search]